Page 1

August 26 , 2021 Can - Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update PETACH TIKVA , Israel -- ( BUSINESS WIRE ) -- Can - Fite BioPharma Ltd. ( NYSE American : CANF ) ( TASE : CFBI ) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory , cancer and liver diseases , today announced financial results for the quarter ended June 30 , 2021 . Corporate and Clinical Development Highlights Include : Can - Fite Entered into Development and Commercialization Agreement in $ 3 Billion Veterinary Osteoarthritis Market - Can - Fite entered into a development and commercialization agreement with Vetbiolix , a France - based veterinary biotech company , for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats . Vetbiolix will have the exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years , during which time Vetbiolix will conduct proof- of - concept studies and cover all associated costs . If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can - Fite , then Vetbiolix will be obligated to pay Can - Fite upfront and milestone payments , in addition to royalties on sales upon regulatory approval for veterinary use . The canine osteoarthritis market is projected to reach $ 3 billion by 2024 . Can - Fite Received a Notice Allowance in China for itsNASH Patent - During the second quarter , Can - Fite received a Notice Allowance in China for its patent titled “ An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation " . This patent , which has subsequently been issued to Can - Fite , addresses the use of the A3 Adenosine Receptor ( A3AR ) ligand , the target receptor for Can - Fite's drug platform technology , to reduce liver fat particularly in patients with NASH . Patent Filed for A3AR - based Cannabis Compounds in the Treatment of Liver Diseases - Can - Fite's preclinical studies of cannabis compounds found CBD rich T3 / C15 induced inhibition of liver cancer cell growth and also had an inhibitory effect on liver fibrosis , which is associated with NAFLD / NASH , cirrhosis , and liver cancer . Can - Fite has filed patent applications to protect its discovery of cannabinoid - based therapies where the A3AR target is overexpressed . Phase III Psoriasis Study Nears Completion of Enrollment- The Phase III Comfort ™ study completed enrollment of 75 % of planned patients during the second quarter , with full enrollment expected in the coming weeks . The study is designed to establish Piclidenoson's superiority compared to placebo and non - inferiority compared to Apremilast ( OtezlaⓇ ) in patients with moderate to severe plaque psoriasis . Topline results are expected Q1 2022 .